ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Avacta Announces FDA Approval of its Investigational New Drug Application for AVA6000
December 02, 2021Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announced that the FDA has approved its Investigational New Drug... -
US FDA approves Avacta Group’s IND application for AVA6000
November 30, 2021The US Food and Drug Administration (FDA) has granted approval to Avacta Group’s Investigational New Drug (IND) application for AVA6000, a new form of doxorubicin. -
Novel chemotherapeutic pro-drug approved for FIH trial in the UK
February 20, 2021If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug’s developers.
Pharma Sources Insight January 2025
